Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

Press/Media

Period15 Nov 2022

Media coverage

1

Media coverage

  • TitleSafety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial
    Media name/outletCritical Care
    Country/TerritoryUnited States
    Date15/11/22
    URLhttps://ccforum.biomedcentral.com/articles/10.1186/s13054-022-04204-9
    PersonsRodica Martin
View all 1
View less